Evidence map›Paper›PMID 41455847›Full record

ArticleAnnals of surgical oncology2026

Axillary Management after Neoadjuvant Endocrine Therapy (NET).

Laura Leonard, Min Yi, Emma Wingate, Puneet Singh, Abigail Caudle, Rosa F Hwang, Isabelle Bedrosian, Vicente Valero, Jennifer Litton, Nuhad Ibrahim and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Laura LeonardBreast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Min YiBreast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Emma WingateBreast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Puneet SinghBreast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abigail CaudleBreast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rosa F HwangBreast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Isabelle BedrosianBreast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vicente ValeroBreast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer LittonBreast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nuhad IbrahimBreast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kelly K HuntBreast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. khunt@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
MD Anderson Cancer Center CA16672NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundIn patients with hormone receptor-positive (HR PATIENTS AND

methodsWe performed a retrospective review of patients with clinical stage I-III, HR

resultsA total of 230 patients were included; 120 (52.2%) were clinically node-negative (cN0), while 110 (47.8%) were clinically node-positive (cN+). In the cN+ group, 7.3% (8/110) had a nodal pathologic complete response (pCR). In total, 76.4% (84/110) in the cN+ group underwent axillary lymph node dissection (ALND) as the initial axillary procedure, and 90.9% (100/110) underwent ALND overall. In total, 98.3% (118/120) with cN0 disease underwent sentinel lymph node dissection (SLND), and 28 (23.7%) had positive nodes. A total of 64.3% (18/28) of cN0 patients with a positive SLN underwent ALND. There were four local-regional recurrences (LRR) in the entire cohort, yielding a 5-year LRR rate of 2.2%, and it did not differ between cN0 and cN+ (2.0% versus 2.2%, p >0.05). The distant recurrence rate was higher in cN+ compared with the cN0 group (15.0% versus 6.9%, p = 0.03). The 5-year overall survival (OS) was 79.5% for the entire cohort and was higher for cN0 compared with cN+ patients (88.4% versus 69.7%, p = 0.004).

conclusionsThe 5-year LRR rate was extremely low for the entire cohort, suggesting that NET is an oncologically safe strategy for patients with HR

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsLymph Node ExcisionNeoadjuvant TherapyAdultAgedAxillaErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansLymphatic MetastasisMiddle AgedPrognosisReceptors, EstrogenReceptors, ProgesteroneAntineoplastic Agents, HormonalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneAxillaBreast cancerNeoadjuvant endocrine therapy (NET)

Identifiers

PMID41455847
PMCPMC12866965

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.